Targanta Study Shows Oritavancin Treatment Effective in a Mouse Model of Anthrax
Single-Dose Protection Observed Prior to or Up to 24 Hours AfterExposure to Anthrax TORONTO, Ontario, May 24, 2007 /PRNewswire/ -- TargantaTherapeutics Corporation announced today the results from a recentstudy demonstrating oritavancin as a potential therapy for treatingexposure to Bacillus anthracis, the bacterium which causes anthrax,an acute infectious disease. Oritavancin, a novel se...